Fusion-VAC-XS15

DRUG2 trials

Sponsors

Universitaetsklinikum Tuebingen AöR, University Hospital Tuebingen

Conditions

Fibrolamellar Hepatocellular Carcinomafibrolamellar heptocelluar carcinomatumor entities carrying the oncogenic driver fusion

Phase 1

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

RecruitingNCT05937295

University Hospital TuebingenFibrolamellar Hepatocellular Carcinoma

Start: 2023-09-26End: 2027-01-31Target: 20Updated: 2024-12-09

FusionVAC22_02: DNAJB1-PRKACA fusion transcript-based peptide vaccine for fibrolamellar hepatocellular carcinoma patients and other tumor entities carrying the oncogenic driver fusion

RecruitingCTIS2024-519387-41-00

Universitaetsklinikum Tuebingen AöRfibrolamellar heptocelluar carcinoma, tumor entities carrying the oncogenic driver fusion

Start: 2025-05-07Target: 20Updated: 2025-06-17

Related Papers

FusionVAC22_02, a phase I clinical trial in progress: Adjuvant <i>DNAJB1-PRKACA</i> fusion transcript–based peptide T-cell activator for fibrolamellar hepatocellular carcinoma (FLC) and other tumor entities carrying the oncogenic driver fusion.

Journal of Clinical Oncology2026-05-28

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

Frontiers in Immunology2024-11-262 citations

FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

Journal of Clinical Oncology2024-06-01

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Frontiers in Oncology2024-03-2810 citations

FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

Journal of Clinical Oncology2024-01-201 citations